MedTrace Logo

A Trial of SHR2285 in Healthy Subjects

NCT04829305 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2022-03-08

No results posted yet for this study

Summary

This is a phase 1 open-label study

Conditions

  • Healthy Volunteers

Interventions

DRUG

SHR2285

SHR2285 is a selective inhibition of human FXIa small molecule compound.

Sponsors & Collaborators

  • Atridia Pty Ltd.

    lead INDUSTRY

Principal Investigators

  • Dr Jasmine Daisy Williams · Study Principal Investigator

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-20
Primary Completion
2021-09-06
Completion
2021-09-06

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04829305 on ClinicalTrials.gov